Qualified academic and corporate laboratories looking to buy IGF-1 DES require pure, fully characterized reference peptides for precise cellular and biochemical assays. PX1 Research delivers analytical-grade Des(1-3)IGF-1 synthesized in GMP-compliant USA facilities and verified by independent ISO 17025 accredited testing. Every shipment includes comprehensive lot-specific documentation to support reproducible preclinical investigations.
Qualified academic and corporate laboratories looking to buy IGF-1 DES require pure, fully characterized reference peptides for precise cellular and biochemical assays. PX1 Research delivers analytical-grade Des(1-3)IGF-1 synthesized in GMP-compliant USA facilities and verified by independent ISO 17025 accredited testing. Every shipment includes comprehensive lot-specific documentation to support reproducible preclinical investigations.
Researchers seeking to buy IGF-1 DES (Des(1-3)IGF-1) require validated reference material with verified sequence purity and batch stability. PX1 Research supplies high-purity, USA-manufactured IGF-1 DES formulated strictly for in vitro assays and preclinical laboratory research, backed by lot-specific third-party RP-HPLC and mass spectrometry Certificate of Analysis (COA) documentation.
Obtaining reliable experimental outcomes in growth factor studies depends heavily on the quality of the starting peptide material. Subtle variations in sequence integrity, residual TFA content, or bacterial endotoxin levels can compromise cell culture viability or skew signal transduction assays. When research teams purchase IGF-1 DES research peptide from PX1 Research, they receive analytical-grade reagents manufactured under strict Quality Management Systems (QMS) to ensure consistent molecular mass, correct tertiary disulfide folding, and verified sequence purity.
Our fulfillment infrastructure is optimized specifically for institutional and corporate laboratories across the United States. All orders ship directly from our climate-controlled facilities in California and Arizona, with same-day dispatch available Monday through Friday for in-stock research compounds. Explore our full catalog of research peptides or review our growth factor research guides to examine technical data prior to experimental design.
IGF-1 DES, truncated form known systematically as Des(1-3)IGF-1, is a naturally occurring structural variant of human insulin-like growth factor 1. The peptide sequence consists of 67 amino acids, lacking the tripeptide sequence Gly-Pro-Glu at the N-terminus compared to full-length native IGF-1 (which contains 70 amino acids). This subtle structural modification dramatically alters the biophysical profile and receptor interactions of the peptide in cell-free and cell-based models.
In physiological and laboratory environments, native IGF-1 circulates largely bound to a family of high-affinity IGF Binding Proteins (IGFBPs 1 through 6). These binding proteins modulate the bioactivity, tissue distribution, and clearance rate of the parent peptide. The N-terminal tripeptide deletion in Des(1-3)IGF-1 eliminates key contact residues necessary for high-affinity binding to IGFBPs without impairing the molecule's affinity for the type 1 IGF receptor (IGF-1R).
Because Des(1-3)IGF-1 escapes sequestering by IGFBPs in vitro, a significantly higher proportion of unbound, bioavailable peptide remains free to engage transmembrane receptor tyrosine kinases. Preclinical studies indicate that this lack of affinity for binding proteins results in potent, immediate receptor phosphorylation in cell cultures, making IGF-1 DES an essential tool for investigating direct IGF-1R downstream kinetics without the confounding variable of binding protein sequestration.
The primary mechanism of action for Des(1-3)IGF-1 in laboratory assays involves direct agonist activity at the Type 1 Insulin-like Growth Factor Receptor (IGF-1R), a heterotetrameric transmembrane tyrosine kinase. Upon ligand engagement, IGF-1R undergoes autophosphorylation of intracellular tyrosine residues, initiating intracellular signaling cascades that regulate protein synthesis, cell survival, proliferation, and metabolic activity.
Preclinical data indicate that IGF-1R activation by IGF-1 DES triggers downstream signaling along two primary cascades: the Phosphoinositide 3-kinase (PI3K) / Akt / Mammalian Target of Rapamycin (mTOR) pathway and the Mitogen-Activated Protein Kinase (MAPK) / Extracellular Signal-Regulated Kinase (ERK) pathway. In cultured cell lines, activation of PI3K/Akt leads to phosphorylation and inhibition of glycogen synthase kinase-3 beta (GSK-3β) and tuberous sclerosis complex 2 (TSC2), ultimately promoting ribosomal biogenesis and translation initiation.
In vitro comparative assays demonstrate that because IGF-1 DES is not sequestered by media-bound or cell-secreted IGFBPs, receptor phosphorylation occurs rapidly following peptide administration. Investigators often utilize this short, intense burst of receptor engagement to study transient intracellular signaling events, gene expression profiles, and rapid ion channel modulation in various cell types including skeletal myoblasts, cardiomyocytes, and neuronal progenitor cells.
The scientific literature regarding Des(1-3)IGF-1 spans cellular biology, tissue engineering, neurobiology, and metabolic research. Because of its enhanced potency in cell culture environments, researchers frequently deploy IGF-1 DES to evaluate anabolic signaling, amino acid uptake, and cellular differentiation protocols.
In myoblast cell line models (such as C2C12 murine cells), in vitro studies show that exposure to Des(1-3)IGF-1 accelerates myotube formation and increases expression of myogenic marker genes including MyoD and myogenin. Researchers observing skeletal muscle cell differentiation report enhanced protein deposition and hyperplastic responses compared to cultures treated with equivalent molar doses of native IGF-1, primarily due to the absent inhibitory effect of endogenous IGFBPs secreted by proliferating myoblasts.
Additional laboratory models investigate the neuroprotective and metabolic parameters of truncated IGF-1 variants. Rodent brain slice cultures and primary neuronal cell models demonstrate that IGF-1 DES signaling supports mitochondrial membrane potential under conditions of oxidative stress or nutrient deprivation. In rodent metabolic models, localized administration of truncated IGF-1 variants has been evaluated to determine tissue-specific glucose clearance rates and protein synthesis induction without inducing systemic hypoglycemia.
When evaluating growth factor variants for study design, laboratory personnel must choose the specific analogue that best fits their experimental parameters. The three primary variants evaluated in cell culture and animal models are Native IGF-1, Long R3 IGF-1 (IGF-1 LR3), and Des(1-3)IGF-1 (IGF-1 DES). Each possesses distinct pharmacological dynamics, binding profiles, and biological persistence.
Native IGF-1 retains full affinity for both IGF-1R and all six IGF-binding proteins, rendering its biological half-life moderate but highly dependent on local binding protein concentrations. In contrast, IGF-1 LR3 incorporates a 13-amino-acid N-terminal extension and a substitution at position 3 (Glu3Arg), which severely reduces IGFBP binding and extends the functional half-life to over 20 hours in preclinical models, making it suitable for studies requiring sustained receptor activation. Meanwhile, IGF-1 DES exhibits a shorter half-life due to rapid receptor internalization and enzymatic degradation, but demonstrates up to 10-fold higher local molar potency in vitro compared to native IGF-1. Another complementary peptide evaluated in localized muscle hypertrophy models is Pegylated MGF (Mechano Growth Factor), which operates via distinct splice-variant mechanisms to initiate satellite cell activation.
Selecting among these research compounds depends on whether an assay requires short-duration, high-potency localized signaling (IGF-1 DES), long-duration sustained receptor activation (IGF-1 LR3), or physiological baseline conditions (Native IGF-1). Researchers can explore detailed comparative data in our IGF-1 variant research guide to optimize experimental protocols.
Analytical precision is non-negotiable when purchasing research peptides. Impurities such as truncated deletion sequences, residual cleavage reagents, or organic solvent residues can introduce severe toxicity in cell culture models or interfere with spectrophotometric and mass-based assays.
PX1 Research enforces stringent analytical testing protocols for every lot of IGF-1 DES synthesized. Primary purity is verified using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring a purity threshold of greater than 98.0%. Molecular mass and amino acid identity are confirmed using Electrospray Ionization Mass Spectrometry (ESI-MS) or Matrix-Assisted Laser Desorption/Ionization (MALDI-TOF), ensuring exact sequence match without unwanted post-translational modifications.
Crucially for tissue culture and cellular assays, PX1 Research subjects all peptide lots to chromogenic Limulus Amebocyte Lysate (LAL) testing to quantify bacterial endotoxin levels. Endotoxin contents are verified to remain below 0.1 EU/mg, preventing spurious inflammatory signaling or receptor desensitization in sensitive cellular preparations. Every shipment of our IGF-1 DES peptide includes a downloadable, lot-specific Certificate of Analysis (COA) detailing these exact analytical outputs.
IGF-1 DES is supplied as a sterile, lyophilized (freeze-dried) powder in sealed amber glass vials under inert argon atmosphere to ensure long-term stability during transport and storage. Proper laboratory handling is essential to preserve peptide integrity and prevent degradation prior to assay execution.
To reconstitute lyophilized IGF-1 DES, researchers should use sterile, analytical-grade diluents such as 10–100 mM dilute acetic acid (pH 2.5–3.0) or sterile bacteriostatic water, depending on final concentration requirements and assay compatibility. Because growth factor peptides can adhere to non-treated hydrophobic plastic surfaces, incorporating 0.1% BSA (Bovine Serum Albumin) or HSA into phosphate-buffered saline (PBS) solution during working dilution steps prevents physical loss of peptide.
Lyophilized vials should be stored at -20°C or -80°C upon arrival, protected from light and moisture, where they maintain stability for up to 24 months. Once reconstituted, solution aliquots should be frozen immediately to avoid repeated freeze-thaw cycles, which induce peptide aggregation and structural denaturation. Detailed handling procedures can be reviewed in our comprehensive guide to peptide reconstitution and laboratory storage.
PX1 Research is committed to advancing scientific inquiry by providing verified, high-purity research compounds to institutional laboratories, university centers, and private research organizations. All peptide products in our catalog are synthesized within certified Good Manufacturing Practice (GMP) compliant facilities located entirely in the United States.
By controlling synthesis, purification, freeze-drying, and packaging within USA domestic facilities, PX1 Research eliminates supply chain delays, batch-to-batch variation, and international customs clearance uncertainties. Independent analytical testing is performed by ISO 17025 accredited third-party laboratories, providing completely unbiased structural verification for every lot produced.
For enterprise research labs, university departments, or high-throughput screening operations seeking bulk procurement, PX1 Research provides custom lot reservation, custom synthesis configurations, and volume discounts. Dedicated procurement managers are available to process institutional purchase orders through our wholesale lab accounts hub.
What is the primary difference between IGF-1 DES and native IGF-1?
IGF-1 DES lacks the first three amino acids (Gly-Pro-Glu) at the N-terminus of the native 70-amino-acid IGF-1 sequence. This truncation prevents IGF-1 DES from binding effectively to IGF Binding Proteins (IGFBPs), leading to higher local bioavailable concentrations and significantly increased receptor binding potency in cell culture assays.
What purity standard does PX1 Research guarantee for IGF-1 DES?
PX1 Research guarantees a minimum sequence purity of 98.0% as determined by Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC). Molecular identity is further confirmed via Mass Spectrometry (ESI-MS), and endotoxin levels are verified below 0.1 EU/mg.
How is IGF-1 DES supplied and shipped?
IGF-1 DES is supplied as a lyophilized (freeze-dried) cake or powder in sealed glass vials sealed under inert gas. Orders ship directly from our California or Arizona facilities via climate-controlled expedited logistics to maintain structural integrity.
What reconstitution solvent should be used for IGF-1 DES in cell culture research?
In laboratory protocols, IGF-1 DES is typically reconstituted initially in 10–100 mM acetic acid (pH 2.5–3.0) or sterile bacteriostatic water, then diluted into culture media or PBS containing 0.1% carrier protein (such as BSA) to minimize vessel wall adsorption.
What are the recommended storage conditions for lyophilized IGF-1 DES?
Unopened, lyophilized IGF-1 DES should be stored at -20°C or -80°C in a dry environment protected from direct light. Under these conditions, the lyophilized peptide remains stable for up to 24 months.
Does PX1 Research provide a Certificate of Analysis (COA) with each order?
Yes. Every lot of IGF-1 DES sold by PX1 Research includes a lot-specific Certificate of Analysis detailing third-party RP-HPLC chromatograms, mass spectrometry spectrum analysis, and endotoxin assay results.
Can IGF-1 DES be used in human subjects or clinical research?
No. IGF-1 DES supplied by PX1 Research is strictly intended for laboratory research, in vitro cellular assays, and preclinical non-human studies. It is not licensed, approved, or intended for human or animal diagnostic, therapeutic, or clinical use.
How does IGF-1 DES compare to IGF-1 LR3 in terms of active half-life?
IGF-1 DES has a significantly shorter functional half-life compared to IGF-1 LR3. While IGF-1 LR3 resists binding protein clearance and circulates for over 20 hours in vivo, IGF-1 DES exerts a rapid, localized burst of receptor activation and is internalized quickly, making it ideal for acute localized signal transduction studies.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.